Daily Stock Analysis, EGLT, Egalet Corp, priceseries

Egalet Corp. Daily Stock Analysis
Stock Information
Open
0.01
Close
0.01
High
0.01
Low
0.01
Previous Close
0.01
Daily Price Gain
-0.00
YTD High
0.01
YTD High Date
Jan 18, 2019
YTD Low
0.00
YTD Low Date
Jan 2, 2019
YTD Price Change
0.00
YTD Gain
56.60%
52 Week High
0.74
52 Week High Date
May 9, 2018
52 Week Low
0.00
52 Week Low Date
Dec 19, 2018
52 Week Price Change
-0.72
52 Week Gain
-98.85%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 5. 2017
1.25
Sep 20. 2017
1.38
11 Trading Days
10.59%
Link
LONG
Nov 16. 2017
1.15
Nov 17. 2017
1.23
1 Trading Days
6.52%
Link
LONG
Nov 21. 2017
1.00
Dec 4. 2017
1.18
8 Trading Days
18.41%
Link
Company Information
Stock Symbol
EGLT
Exchange
NasdaqGM
Company URL
http://www.egalet.com
Company Phone
610-833-4200
CEO
Robert Samuel Radie
Headquarters
Pennsylvania
Business Address
600 LEE ROAD, SUITE 100, WAYNE, PA 19087
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001586105
About

Egalet Corp. engages in developing and manufacturing pharmaceutical products. Its products include ARYMO, OXAYDO, and SPRIX Nasal Spray. The company was founded by Jean-Francois B. Formela in August 2013 and is headquartered in Wayne, PA.

Description

Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The company is also developing Egalet-002, a Guardian Technology AD, ER, oral oxycodone formulation, which is in Phase III clinical trials for the same indication as ARYMO ER. In addition, its other products include Egalet-003, an AD stimulant product candidate; and Egalet-004, an AD, ER hydrocodone-based product candidate. The company has a collaboration and license agreement with Acura Pharmaceuticals, Inc. to commercialize OXAYDO tablets; and Septodont, Inc. to promote SPRIX Nasal Spray. Egalet Corporation was founded in 2010 and is headquartered in Wayne, Pennsylvania.